After demonstrating that intestinal rejuvenation procedures can bring various benefits to chronic diseases, the newly renamed Fractyl Health will spend $ 100 million to help continue treatment at the finish line. I procured it.
Formerly known as Fractyl Laboratories, the company manufactures Revita DMR, an endoscope device that uses water and heat to remove the lining of the duodenum of the small intestine. This device essentially flushes the mucosal layer of the duodenum with pressure. The mucosal layer can be thickened by years of dietary fat, sugar, and other foods.
This region of the organ is also involved in the production of hormones that control metabolism, and imbalances may be the root cause of type 2 diabetes, contributing to insulin resistance and the need for daily injections. I will.
40 minutes outpatient treatment of fractil by cleaning the duodenum and re-growing a healthy lamina propria over time is showing It can result in long-term glycemic control and increased liver fat, and may allow some patients to go without insulin for at least 6 months.
“We believe we have discovered a new way to treat metabolic disorders by controlling the duodenum, the body’s central metabolic control organ,” said Harith Rajagopalan, co-founder and CEO of Fracytl. It states as follows. statement..
Income from the former Fierce 15 winners The Series F Round will help secure the FDA’s green light for type 2 diabetes and help initiate multiple late-stage clinical trials aimed at expanding production internationally. Revita has already received groundbreaking designations from distributors and is CE marked in Europe.
The company was randomized, Fake controlled research Type 2 diabetes aims to attract more than 400 participants to see if this procedure can improve glycemic control without the need for insulin for more than 6 months.
Mark Area, the founder of M28 Capital, said: It co-led a round with Maverick Capital and Population Health Partners, with participation from other unnamed investors.
Less than a year ago, Fractil finished the Series E round, Taiwan, Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergency Medical Partners, True Ventures, GV, Catalio Capital Management, CDIB Venture Capital, YJ Capital.
In the future, cancer, organ failure, and other metabolisms that may lead to the need for transplants if left untreated, such as non-alcoholic steatohepatitis and non-alcoholic steatohepatitis called NAFLD or NASH. I plan to work on sexual illness.
https://www.fiercebiotech.com/medtech/fractyl-nets-100m-to-complete-development-its-intestine-washing-device-for-type-2-diabetes Fractyl has won $ 100 million to complete the development of an intestinal cleanser for type 2 diabetes